Why should the growth of children on ICS be monitored?

Monitoring the growth of children on inhaled corticosteroids (ICS) is critical due to the potential for suppression of growth or delay in growth. ICS are effective in managing asthma symptoms by reducing inflammation in the airways, but their systemic effects at higher doses, particularly in the pediatric population, can impact growth.

The growth-suppressive effect is particularly a concern because the use of corticosteroids can lead to reduced growth velocity during periods of physical development. While they are essential for managing asthma effectively, healthcare providers must balance the benefits of asthma control against potential side effects, including growth impairment. Therefore, regular monitoring is necessary to assess the child's growth patterns and ensure that any potential impact is addressed promptly. If growth suppression is documented, adjustments in medication or dosages may be necessary to optimize treatment and support healthy growth.

This approach aligns with pediatric care standards, where careful consideration of both respiratory health and physical development is vital for the overall well-being of the child.